Scarica l'app Stockscreener
6.23
5.61%
-0.37
Precedente Chiudi:
$6.60
Aprire:
$6.67
Volume 24 ore:
1.96M
Relative Volume:
2.42
Capitalizzazione di mercato:
$368.17M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
118.89
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
+15.58%
1M Prestazione:
+41.27%
6M Prestazione:
+34.56%
1 anno Prestazione:
+34.85%
Intervallo 1D:
$6.15
$6.6957
Intervallo di 1 settimana:
$5.42
$6.88
Portata 52W:
$3.8092
$6.88
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Confronta VNDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.23 | 390.04M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Iniziato | B. Riley Securities | Buy |
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference - The AI Journal
FDA lifts partial clinical hold on Vanda Pharmaceuticals’ tradipitant - MSN
Vanda Pharmaceuticals Inc. $VNDA Holdings Cut by Schroder Investment Management Group - MarketBeat
Stonepine Capital Management LLC Has $1.18 Million Position in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
What insider trading reveals about Vanda Pharmaceuticals Inc. stockStop Loss & Real-Time Volume Surge Alerts - Newser
Vanda jumps as FDA lifts tradipitant partial clinical hold - MSN
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - The Malaysian Reserve
Vanda Pharmaceuticals (VNDA) Soars After FDA Lifts Tradipitant H - GuruFocus
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickne - GuruFocus
Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study - marketscreener.com
FDA lifts partial clinical hold on Vanda’s tradipitant for motion sickness - Investing.com India
FDA Lifts Hold on Vanda’s Tradipitant Trials - TipRanks
FDA Lifts Hold on Vanda Pharmaceuticals' (VNDA) Tradipitant Stud - GuruFocus
Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold By Investing.com - Investing.com Canada
Will Vanda Pharmaceuticals Inc. (VM4) stock see insider accumulation2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Vanda Pharmaceuticals (VNDA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Vanda Pharmaceuticals Inc. (VM4) stock attractive for growth fundsMarket Activity Report & Low Risk Growth Stock Ideas - Newser
Will Vanda Pharmaceuticals Inc. (VM4) stock benefit from mergersWeekly Stock Report & Weekly Setup with High ROI Potential - Newser
Vanda Pharma (NASDAQ: VNDA) wins FDA lift as tradipitant NDA review stays on track - Stock Titan
Can Vanda Pharmaceuticals Inc. (VM4) stock double in coming years2025 Risk Factors & Free Long-Term Investment Growth Plans - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to new regulations2025 Volatility Report & Daily Oversold Bounce Ideas - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock moves in volatile trading sessionsPortfolio Gains Summary & AI Optimized Trading Strategy Guides - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to weak economy - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to monetary easingProfit Target & Risk Controlled Stock Alerts - Newser
Will Vanda Pharmaceuticals Inc. stock pay special dividends - Newser
H.C. Wainwright reiterates Buy rating on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Vanda Pharmaceuticals (Nasdaq:VNDA) Provides Key Regulatory Update on Motion Sickness Therapy - Kalkine Media
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by Wall Street Zen - MarketBeat
FDA Extends Review of Vanda Pharmaceuticals' (VNDA) Tradipitant - GuruFocus
FDA re-review of Vanda tradipitant partial clinical hold extended - Seeking Alpha
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - GuruFocus
Vanda Pharmaceuticals (VNDA) Updates on Tradipitant for Motion S - GuruFocus
Vanda Pharmaceuticals Updates on Tradipitant FDA Review - TipRanks
Vanda Pharmaceuticals provides regulatory update on Tradipitant for motion sickness - marketscreener.com
Vanda Pharmaceuticals Provides Regulatory Update On Tradipitant For Motion Sickness - TradingView
Vanda Pharmaceuticals Inc Provides Regulatory Update on Tradipitant - TradingView
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness – Company Announcement - Financial Times
Published on: 2025-11-28 08:55:55 - moha.gov.vn
Will Vanda Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Sector Moves & Fast Gaining Stock Reports - BỘ NỘI VỤ
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder (PR Newswire) - Aktiellt
Vanda Sees Sales Jump, But Losses Also Pile Up - Finimize
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Vanda a new buy at B. Riley on 'historic discount' - MSN
Will Vanda Pharmaceuticals Inc. (VM4) stock test record highs in 2025Wall Street Watch & Capital Efficient Trade Techniques - newser.com
Vanda Pharmaceuticals Leads 3 Promising Penny Stocks - Yahoo Finance
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects - MSN
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality (NASDAQ:VNDA) - Seeking Alpha
Vanda Reports Big Win In Wegovy Support Study, Analysts UpbeatVanda Pharmaceuticals (NASDAQ:VNDA) - Benzinga
Is Vanda Pharmaceuticals Inc. (VM4) stock trading at attractive multiples2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vanda Pharmaceuticals Inc Azioni (VNDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):